{"DataElement":{"publicId":"2950698","version":"5","preferredName":"Disease or Disorder Lymphoma Histology Classification Type","preferredDefinition":"A description of the lymphoma histology classification.","longName":"3128015v1.00:2947251v2.10","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3128015","version":"1","preferredName":"Disease or Disorder Histology","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","longName":"2404658v1.0:2186387v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2186387","version":"1","preferredName":"Histology","preferredDefinition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","longName":"C16681","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histology","conceptCode":"C16681","definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0647F5B-A9B0-4B87-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-08-03","modifiedBy":"DWARZEL","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D7B1C96-9767-5C40-E040-BB89AD4372AD","latestVersionIndicator":"Yes","beginDate":"2010-08-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2010-08-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2947251","version":"2.1","preferredName":"Lymphoma Histology Classification Type","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites.  This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics._Something distinguishable as an identifiable class based on common qualities.","longName":"2947251v2.10","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Classic Hodgkin lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2838033","version":"1","preferredName":"Classical Hodgkin Lymphoma","longName":"2838033","preferredDefinition":"In more than 95% of cases, a monoclonal B-cell lymphoproliferation characterized by a bimodal age distribution (15-30 years of life and late life), often associated with EBV infection.  In less than 5% of cases, this is a monoclonal proliferation of T-lymphocytes. Morphologically, it is characterized by the presense of Reed-Sternberg cells and mononuclear Hodgkin cells.  The Reed-Sternberg and mononuclear Hodgkin cells are CD30 positive in nearly all cases and CD15 positive in the majority of cases.  -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classic Hodgkin Lymphoma","conceptCode":"C7164","definition":"A category of Hodgkin lymphomas that includes the following four histologic subtypes: lymphocyte-rich, nodular sclerosis, mixed cellularity, and lymphocyte-depleted classic Hodgkin lymphoma. The vast majority of Hodgkin lymphomas belong to this category.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-842C-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C252-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Lymphocyte depleted","valueDescription":null,"ValueMeaning":{"publicId":"2593114","version":"1","preferredName":"Lymphocyte Depleted Hodgkin Lymphoma","longName":"2593114","preferredDefinition":"A diffuse form of classical Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes.  Historically, the clinical course of this type of Hodgkin lymphoma was aggressive.  With current therapy, the course is comparable to patients with other subtypes of classical Hodgkin lymphoma.  Most patients present with advanced stage disease (Stage III or IV) and B-symptoms. (WHO, 2001) -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte-Depleted Classic Hodgkin Lymphoma","conceptCode":"C9283","definition":"A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D2655-C796-1ADB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C253-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Lymphocyte-rich","valueDescription":null,"ValueMeaning":{"publicId":"2945134","version":"1","preferredName":"Lymphocyte rich","longName":"2945134v1.00","preferredDefinition":"A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte-Rich Classic Hodgkin Lymphoma","conceptCode":"C6913","definition":"A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7455393D-DF80-CE7B-E040-BB89AD4334EC","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-09-24","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C254-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Mixed cellularity","valueDescription":null,"ValueMeaning":{"publicId":"4973638","version":"1","preferredName":"Mixed Cellularity Classical Hodgkin Lymphoma","longName":"4973638","preferredDefinition":"A subtype of classical Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Cellularity Classic Hodgkin Lymphoma","conceptCode":"C3517","definition":"A subtype of classic Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88C8D5-A82F-472E-E050-BB89AD434958","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C255-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Nodular lymphocyte predominant Hodgkin lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2838645","version":"1","preferredName":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","longName":"2838645","preferredDefinition":"A monoclonal B-cell neoplasm characterized by a nodular, or a nodular and diffuse, polymorphous proliferation of scattered large neoplastic cells known as popcorn or L&H cells; the L&H cells are CD15 negative, and rarely positive for CD30 antigen.  Patients are predominantly male, frequently in the 30-50 year age group.  Most patients present with limited stage disease (localized peripheral lymphadenopathy, stage I or II); the prognosis of patients with stage I and stage II disease is very good.  Advanced stages have an unfavorable prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Lymphocyte Predominant B-Cell Lymphoma","conceptCode":"C7258","definition":"A B-cell lymphoma characterized by the presence of scattered clonal cells known as lymphocyte predominant cells (LP cells) in a background of reactive lymphocytes and histiocytes, and formation of a nodular or nodular and diffuse growth pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9584-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"DWARZEL","dateModified":"2012-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C256-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Nodular sclerosis","valueDescription":null,"ValueMeaning":{"publicId":"4973639","version":"1","preferredName":"Nodular Sclerosis Classical Hodgkin Lymphoma","longName":"4973639","preferredDefinition":"A subtype of classical Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Sclerosis Classic Hodgkin Lymphoma","conceptCode":"C3518","definition":"A subtype of classic Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88C8D5-A86A-472E-E050-BB89AD434958","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C257-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Burkitt lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"4173731","version":"1","preferredName":"Burkitt Lymphoma","longName":"4173731","preferredDefinition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Lymphoma","conceptCode":"C2912","definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F33D05F6-4928-3FBE-E040-BB89AD433F7A","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C258-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"ALK-positive large B-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"5990015","version":"1","preferredName":"ALK-Positive Large B-Cell Lymphoma","longName":"5990015","preferredDefinition":"A usually aggressive large B-cell lymphoma characterized by the presence of monomorphic immunoblast-like neoplastic B-lymphocytes in a sinusoidal growth pattern.  The neoplastic B-lymphocytes express the ALK kinase but they lack the 2;5 translocation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ALK-Positive Large B-Cell Lymphoma","conceptCode":"C7225","definition":"A usually aggressive large B-cell lymphoma characterized by the presence of monomorphic immunoblast-like neoplastic B-lymphocytes in a sinusoidal growth pattern.  The neoplastic B-lymphocytes express the ALK kinase but they lack the 2;5 translocation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE3CC3C-9C3C-3E53-E053-F662850A6BF9","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C259-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Diffuse large B-cell lymphoma - Activated B-cell type subtype","valueDescription":null,"ValueMeaning":{"publicId":"3185301","version":"1","preferredName":"Non-GCB","longName":"3185301v1.00","preferredDefinition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 30% of diffuse large B-cell lymphomas, and is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes.  Morphologically, these lymphomas are either centroblastic or immunoblastic (ratio 2:1).  Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome compared to those with a germinal center B-cell expression profile, with a 5-year survival rate of 35% and a median survival of 2 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma Activated B-Cell Type","conceptCode":"C36081","definition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 30% of diffuse large B-cell lymphomas, and is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes.  Morphologically, these lymphomas are either centroblastic or immunoblastic (ratio 2:1).  Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome compared to those with a germinal center B-cell expression profile, with a 5-year survival rate of 35% and a median survival of 2 years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A602691-7F00-B189-E040-BB89AD437FA7","latestVersionIndicator":"Yes","beginDate":"2011-01-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-21","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C25A-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Diffuse large B-cell lymphoma associated with chronic inflammation","valueDescription":null,"ValueMeaning":{"publicId":"5989997","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation","longName":"5989997","preferredDefinition":"A diffuse large B-cell lymphoma arising in body cavities or narrow spaces of long standing chronic inflammation.  The classic example is the pyothorax-associated lymphoma that arises in the pleural cavity of patients with a history of long standing pyothorax.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation","conceptCode":"C80289","definition":"A diffuse large B-cell lymphoma arising in body cavities or narrow spaces of long standing chronic inflammation.  The classic example is the pyothorax-associated lymphoma that arises in the pleural cavity of patients with a history of long standing pyothorax.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE36C42-4E6F-4196-E053-F662850A806E","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C25B-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Diffuse large B-cell lymphoma - Germinal Center B-cell subtype","valueDescription":null,"ValueMeaning":{"publicId":"3185303","version":"1","preferredName":"GCB","longName":"3185303v1.00","preferredDefinition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 50% of diffuse large B-cell lymphomas, and is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.  Morphologically, the vast majority of these lymphomas are centroblastic and a small minority are immunoblastic (ratio20:1).  Patients with this type of diffuse large B-cell lymphoma have a more favorable outcome, with a 5-year survival rate of 60% and a median survival of 10 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","conceptCode":"C36080","definition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 50% of diffuse large B-cell lymphomas, and is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.  Morphologically, the vast majority of these lymphomas are centroblastic and a small minority are immunoblastic (ratio20:1).  Patients with this type of diffuse large B-cell lymphoma have a more favorable outcome, with a 5-year survival rate of 60% and a median survival of 10 years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A602691-7F26-B189-E040-BB89AD437FA7","latestVersionIndicator":"Yes","beginDate":"2011-01-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-21","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C25C-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Diffuse large B-cell lymphoma / high-grade B-cell lymphoma with MYC and BCL2 rearrangements","valueDescription":null,"ValueMeaning":{"publicId":"14679087","version":"1","preferredName":"High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements","longName":"14679087v1.00","preferredDefinition":"High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC and BCL2 genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements","conceptCode":"C199617","definition":"High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC and BCL2 genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0D3-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C25D-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements","valueDescription":null,"ValueMeaning":{"publicId":"5990024","version":"1","preferredName":"High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements","longName":"5990024","preferredDefinition":"A rare B-cell non-Hodgkin lymphoma that is characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and/ or BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements","conceptCode":"C131913","definition":"High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE4228F-597F-2DAA-E053-F662850A70BC","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C25E-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Diffuse large B-cell lymphoma, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"3928526","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","longName":"3928526","preferredDefinition":"A term referring to a group of diffuse large B-cell lymphomas which are biologically heterogeneous and lack definitive and accepted criteria for further subclassification.  These lymphomas have a centroblastic, immunoblastic, or anaplastic morphology.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C80280","definition":"A term referring to a group of diffuse large B-cell lymphomas which are biologically heterogeneous. These lymphomas have a centroblastic, immunoblastic, or anaplastic morphology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3CB3-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C25F-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"EBV-positive diffuse large B-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"6002230","version":"1","preferredName":"EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","longName":"6002230","preferredDefinition":"A diffuse large B-cell lymphoma originally described in patients older than 50 years but it has been increasingly recognized in younger patients. Epstein-Barr virus is present in all cases. There is no known history of immunodeficiency or prior lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C80281","definition":"A diffuse large B-cell lymphoma originally described in patients older than 50 years, but it has been increasingly recognized in younger patients. Epstein-Barr virus is present in all cases. There is no known history of immunodeficiency or prior lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5912CE-943E-4D2E-E053-F662850A3D9C","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C260-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Fibrin-associated large B-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"14679088","version":"1","preferredName":"Fibrin-Associated Diffuse Large B-Cell Lymphoma","longName":"14679088v1.00","preferredDefinition":"An unusual form of diffuse large B-cell lymphoma. It is not mass-forming and does not directly produce symptoms, but it is discovered incidentally on histological examination of surgical pathology specimens, excised for various pathologies other than lymphoma. The specimens typically contain fibrinous materials. Single and small aggregates of large lymphoma cells are found in only small foci within the fibrinous or amorphous material. EBV is positive, with type III latency. The clinical outcome is highly favorable, even with surgical excision alone. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibrin-Associated Diffuse Large B-Cell Lymphoma","conceptCode":"C150396","definition":"An unusual form of diffuse large B-cell lymphoma. It is not mass-forming and does not directly produce symptoms, but it is discovered incidentally on histological examination of surgical pathology specimens, excised for various pathologies other than lymphoma. The specimens typically contain fibrinous materials. Single and small aggregates of large lymphoma cells are found in only small foci within the fibrinous or amorphous material. EBV is positive, with type III latency. The clinical outcome is highly favorable, even with surgical excision alone. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0D4-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C261-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"High-grade B-cell lymphoma with 11q aberration","valueDescription":null,"ValueMeaning":{"publicId":"5989995","version":"1","preferredName":"MYC-Negative B-Cell Lymphoma with 11q Aberration Resembling Burkitt Lymphoma","longName":"5989995","preferredDefinition":"A molecularly distinct B-cell lymphoma reminiscent of Burkitt lymphoma. It is characterized by the absence of MYC translocation and the presence of chromosome 11q aberrations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt-Like Lymphoma with 11q Aberration","conceptCode":"C131911","definition":"A molecularly distinct B-cell lymphoma reminiscent of Burkitt lymphoma. It is characterized by the absence of MYC translocation and the presence of chromosome 11q aberrations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE36C42-4E49-4196-E053-F662850A806E","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C262-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Intravascular large B-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2947252","version":"1","preferredName":"Intravascular Large B-Cell Lymphoma","longName":"2947252","preferredDefinition":"A rare extranodal B-cell non-Hodgkin lymphoma, characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.  This is an extremely aggressive lymphoma which responds poorly to chemotherapy.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravascular Large B-Cell Lymphoma","conceptCode":"C4342","definition":"A rare extranodal B-cell non-Hodgkin lymphoma, characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.  This is an extremely aggressive lymphoma which responds poorly to chemotherapy.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74B9639F-F1F8-0172-E040-BB89AD436135","latestVersionIndicator":"Yes","beginDate":"2009-09-29","endDate":null,"createdBy":"SCOTTLO","dateCreated":"2009-09-29","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C263-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Large B-cell lymphoma with IRF4 rearrangement","valueDescription":null,"ValueMeaning":{"publicId":"5990013","version":"1","preferredName":"Large B-Cell Lymphoma with IRF4 Rearrangement","longName":"5990013","preferredDefinition":"A germinal center-derived B-cell lymphoma that affects predominantly children and young adults. It is characterized by the presence of strong IRF4 expression and IRF4 translocation, BCL2 expression, and the absence of t(14;18)(q32;q21). It affects the Waldeyer's ring, head and neck lymph nodes, and the intestine. Morphologically it is characterized by the presence of diffuse and grade 3 follicular areas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large B-Cell Lymphoma with IRF4 Rearrangement","conceptCode":"C133494","definition":"A large B-cell lymphoma that usually affects the Waldeyer ring and/or cervical lymph nodes and less often the gastrointestinal tract. It occurs most commonly in children and young adults and is low stage. It is characterized by a follicular, follicular and diffuse, or pure diffuse growth pattern resembling follicular lymphoma grade 3B or a diffuse large B-cell lymphoma. Most cases have IG/IRF4 rearrangements. BCL2 rearrangements are not present. Some cases that belong in this category lack an IRF4 rearrangement but have strong IRF4/MUM1 expression. This lymphoma is more aggressive than pediatric-type follicular lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE3CC3C-9C16-3E53-E053-F662850A6BF9","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C264-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Lymphomatoid granulomatosis","valueDescription":null,"ValueMeaning":{"publicId":"2838594","version":"1","preferredName":"Lymphomatoid Granulomatosis","longName":"2838594","preferredDefinition":"An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphomatoid Granulomatosis","conceptCode":"C7930","definition":"An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F7F1-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C265-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Mediastinal grey zone lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"14679089","version":"1","preferredName":"Mediastinal Gray-Zone Lymphoma","longName":"14679089v1.00","preferredDefinition":"A mediastinal lymphoma with molecular, morphologic, immunophenotypic, and clinical features of both mediastinal (thymic) large B-cell lymphoma and classic Hodgkin lymphoma.  The identification of this group of lymphomas, along with recent gene expression profiling results (PDL2 gene expression in both mediastinal (thymic) large B-cell lymphoma tissues and Hodgkin lymphoma cell lines), further supports the hypothesis that mediastinal (thymic) large B-cell lymphomas and classic Hodgkin lymphomas are related entities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mediastinal Gray-Zone Lymphoma","conceptCode":"C37870","definition":"A mediastinal lymphoma with molecular, morphologic, immunophenotypic, and clinical features of both mediastinal (thymic) large B-cell lymphoma and classic Hodgkin lymphoma.  The identification of this group of lymphomas, along with recent gene expression profiling results (PDL2 gene expression in both mediastinal (thymic) large B-cell lymphoma tissues and Hodgkin lymphoma cell lines), further supports the hypothesis that mediastinal (thymic) large B-cell lymphomas and classic Hodgkin lymphomas are related entities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0D5-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C266-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Plasmablastic lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"3785911","version":"1","preferredName":"Plasmablastic Lymphoma","longName":"3785911","preferredDefinition":"An aggressive diffuse large B-cell lymphoma usually arising in the setting of HIV infection and characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells.  Sites of involvement include the oral cavity, sinonasal cavity, skin, soft tissues, gastrointestinal tract, and bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasmablastic Lymphoma","conceptCode":"C7224","definition":"An aggressive diffuse large B-cell lymphoma frequently arising in the setting of HIV infection and characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells.  Sites of involvement include the oral cavity, sinonasal cavity, skin, soft tissues, gastrointestinal tract, and bone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF0AC481-08BA-CBF9-E040-BB89AD434A4F","latestVersionIndicator":"Yes","beginDate":"2013-06-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-06-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C267-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary cutaneous diffuse large B-cell lymphoma, leg type","valueDescription":null,"ValueMeaning":{"publicId":"7332091","version":"1","preferredName":"Cervical Adenosquamous Carcinoma","longName":"7332091","preferredDefinition":"An uncommon carcinoma arising from the cervix.  It is composed of malignant glandular epithelial cells and malignant squamous epithelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Adenosquamous Carcinoma","conceptCode":"C4519","definition":"An uncommon carcinoma arising from the cervix.  It is composed of malignant glandular epithelial cells and malignant squamous epithelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A826878D-5CB8-4AF5-E053-4EBD850A14F0","latestVersionIndicator":"Yes","beginDate":"2020-06-15","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-06-15","modifiedBy":"ONEDATA","dateModified":"2020-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C268-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary mediastinal large B-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2838609","version":"1","preferredName":"Mediastinal (Thymic) Large B-Cell Lymphoma","longName":"2838609","preferredDefinition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Mediastinal Large B-Cell Lymphoma","conceptCode":"C9280","definition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AEF5-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C269-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"T-cell / histiocytic-rich large B-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"3928520","version":"1","preferredName":"T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","longName":"3928520","preferredDefinition":"A large B-cell lymphoma characterized by the presence of a limited number of scattered neoplastic large B-lymphocytes which are admixed with numerous non-neoplastic T-lymphocytes and frequently histiocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","conceptCode":"C9496","definition":"A large B-cell lymphoma characterized by the presence of a limited number of scattered neoplastic large B-lymphocytes which are admixed with numerous non-neoplastic T-lymphocytes and frequently histiocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3C2D-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C26A-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"High-grade B-cell lymphoma, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"3928524","version":"1","preferredName":"High Grade B-Cell Lymphoma, Not Otherwise Specified","longName":"3928524","preferredDefinition":"An aggressive lymphoma with morphologic features of both diffuse large B-cell lymphoma and Burkitt lymphoma, but without rearrangement of MYC gene, BCL2 gene and/or BCL6 gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade B-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C80291","definition":"High-grade B-cell lymphoma with blastoid features or features between diffuse large B-cell lymphoma and Burkitt lymphoma that lacks MYC, BCL2, and BCL6 gene rearrangements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3C79-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C26B-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary large B-cell lymphoma of the CNS","valueDescription":null,"ValueMeaning":{"publicId":"3928506","version":"1","preferredName":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","longName":"3928506","preferredDefinition":"A diffuse large B-cell lymphoma arising from the central nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","conceptCode":"C71720","definition":"A diffuse large B-cell lymphoma arising from the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-33C9-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C26C-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary large B-cell lymphoma of the testis","valueDescription":null,"ValueMeaning":{"publicId":"14679090","version":"1","preferredName":"Testicular Diffuse Large B-Cell Lymphoma","longName":"14679090v1.00","preferredDefinition":"A diffuse large B-cell lymphoma that arises from the testis. It predominantly affects older men. Patients usually present with a unilateral hard painless mass. Bilateral masses have been described in a minority of patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testicular Diffuse Large B-Cell Lymphoma","conceptCode":"C162467","definition":"A diffuse large B-cell lymphoma that arises from the testis. It predominantly affects older men. Patients usually present with a unilateral hard painless mass. Bilateral masses have been described in a minority of patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0D6-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C26D-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary large B-cell lymphoma of the vitreoretina","valueDescription":null,"ValueMeaning":{"publicId":"14679091","version":"1","preferredName":"Primary Vitreoretinal Diffuse Large B-Cell Lymphoma","longName":"14679091v1.00","preferredDefinition":"An uncommon and potentially fatal diffuse large B-cell lymphoma that involves the uvea, retina, vitreous body, and optic nerve. It is a subset of primary central nervous system diffuse large B-cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Vitreoretinal Diffuse Large B-Cell Lymphoma","conceptCode":"C157067","definition":"An uncommon and potentially fatal diffuse large B-cell lymphoma that involves the uvea, retina, vitreous body, and optic nerve. It is a subset of primary central nervous system diffuse large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0D7-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C26E-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"KSHV / HHV8-positive diffuse large B-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"6002242","version":"1","preferredName":"HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","longName":"6002242","preferredDefinition":"A B-cell lymphoma characterized by the presence of a diffuse proliferation of large, atypical HHV8-positive, EBV-negative neoplastic lymphocytes. Areas of multicentric Castleman disease are not present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C138320","definition":"A large B-cell lymphoma characterized by the presence of a diffuse proliferation of large, atypical HHV8-positive neoplastic lymphocytes. It usually arises in association with HHV8-positive multicentric Castleman disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5912CE-9536-4D2E-E053-F662850A3D9C","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C26F-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary effusion lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2838711","version":"1","preferredName":"Primary Effusion Lymphoma","longName":"2838711","preferredDefinition":"An aggressive non-Hodgkin B-cell lymphoma composed of large cells, presenting as a serous effusion without detectable tumor masses.  It is universally associated with human herpes virus 8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV) [HHV-8/KSHV].  It mostly occurs in the setting of immunodeficiency; most cases have been reported in HIV positive patients.  The most common sites of involvement are the pleural, pericardial, and peritoneal cavities.  The prognosis is extremely unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Effusion Lymphoma","conceptCode":"C6915","definition":"A large B-cell lymphoma usually presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Rare HHV8-positive lymphomas indistinguishable from primary effusion lymphomas (PEL) present as solid tumor masses, and have been termed extracavitary PEL. The prognosis is extremely unfavorable. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A7EC44-0A6F-AA83-E040-BB89AD437747","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C270-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Lymphoplasmacytic lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2629954","version":"1","preferredName":"Lymphoplasmacytic Lymphoma","longName":"2629954","preferredDefinition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoplasmacytic Lymphoma","conceptCode":"C3212","definition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E665ACD-9834-52CE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-18","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-04-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Added NCIt concept.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C271-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"IgM-LPL / Waldenstrom macroglobulinemia","valueDescription":null,"ValueMeaning":{"publicId":"14679092","version":"1","preferredName":"IgM Secreting Waldenstrom Macroglobulinemia","longName":"14679092v1.00","preferredDefinition":"A finding of Waldenstrom macroglobulinemia in which the neoplastic cells secrete IgM. Secretion of an immunoglobulin other than IgM is rare.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IgM Secreting Waldenstrom Macroglobulinemia","conceptCode":"C203439","definition":"A finding of Waldenstrom macroglobulinemia in which the neoplastic cells secrete IgM. Secretion of an immunoglobulin other than IgM is rare.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0D8-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C272-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Non-IgM-LPL / Waldenstrom macroglobulinemia","valueDescription":null,"ValueMeaning":{"publicId":"14679093","version":"1","preferredName":"Non-IgM Secreting Waldenstrom Macroglobulinemia","longName":"14679093v1.00","preferredDefinition":"A rare finding of Waldenstrom macroglobulinemia in which the neoplastic cells secrete an immunoglobulin other than IgM.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-IgM Secreting Waldenstrom Macroglobulinemia","conceptCode":"C203438","definition":"A rare finding of Waldenstrom macroglobulinemia in which the neoplastic cells secrete an immunoglobulin other than IgM.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0D9-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C273-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue","valueDescription":null,"ValueMeaning":{"publicId":"4722745","version":"1","preferredName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","longName":"4722745","preferredDefinition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","conceptCode":"C3898","definition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C4AE-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C274-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Nodal marginal zone lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"4722746","version":"1","preferredName":"Nodal Marginal Zone Lymphoma","longName":"4722746","preferredDefinition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  This is a rare entity, and most patients present with localized or generalized lymphadenopathy.  The clinical course is indolent.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal Marginal Zone Lymphoma","conceptCode":"C8863","definition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C535-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C275-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Pediatric marginal zone lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"5989989","version":"1","preferredName":"Pediatric Nodal Marginal Zone Lymphoma","longName":"5989989","preferredDefinition":"A nodal marginal zone lymphoma affecting the pediatric population, predominantly males.  It presents with asymptomatic and localized (mainly head and neck) disease in the vast majority of cases.  Morphologically there is often progressive transformation of the germinal centers.  The prognosis is excellent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pediatric Nodal Marginal Zone Lymphoma","conceptCode":"C80299","definition":"A nodal marginal zone lymphoma affecting the pediatric population, predominantly males.  It presents with asymptomatic and localized (mainly head and neck) disease in the vast majority of cases.  Morphologically there is often progressive transformation of the germinal centers.  The prognosis is excellent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE35A9C-09B3-3EA2-E053-F662850A4384","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C276-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary cutaneous marginal zone lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"14679094","version":"1","preferredName":"Primary Cutaneous Marginal Zone Lymphoproliferative Disorder","longName":"14679094v1.00","preferredDefinition":"A B-cell lymphoproliferative disorder that arises from the skin. It was previously known as primary cutaneous marginal zone lymphoma of mucosa-associated lymphoid tissue. Two subtypes are recognized: heavy chain class-switched primary cutaneous marginal zone lymphoproliferative disorder and IgM-positive primary cutaneous marginal zone lymphoproliferative disorder. The majority of cases are class-switched and predominantly IgG-positive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous Marginal Zone Lymphoproliferative Disorder","conceptCode":"C7230","definition":"A B-cell lymphoproliferative disorder that arises from the skin. It was previously known as primary cutaneous marginal zone lymphoma of mucosa-associated lymphoid tissue. Two subtypes are recognized: heavy chain class-switched primary cutaneous marginal zone lymphoproliferative disorder and IgM-positive primary cutaneous marginal zone lymphoproliferative disorder. The majority of cases are class-switched and predominantly IgG-positive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0DA-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C277-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Splenic, B-cell lymphoma / leukemia with prominent nucleoli","valueDescription":null,"ValueMeaning":{"publicId":"5376573","version":"1","preferredName":"Hairy Cell Leukemia Variant","longName":"5376573","preferredDefinition":"An indolent chronic B-cell leukemia resembling classic hairy cell leukemia but shows variant cytologic, hematologic, and immunophenotypic features and is resistant to the conventional therapy applied to hairy cell leukemia.  Biologically, it is not related to hairy cell leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hairy Cell Leukemia Variant","conceptCode":"C7401","definition":"An indolent chronic B-cell leukemia resembling classic hairy cell leukemia but shows variant cytologic, hematologic, and immunophenotypic features and is resistant to the conventional therapy applied to hairy cell leukemia.  Biologically, it is not related to hairy cell leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"392E1632-9663-21CD-E050-BB89AD43368A","latestVersionIndicator":"Yes","beginDate":"2016-08-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C278-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Splenic diffuse red pulp small B-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"5989991","version":"1","preferredName":"Splenic Diffuse Red Pulp Small B-Cell Lymphoma","longName":"5989991","preferredDefinition":"An uncommon, indolent B-cell non-Hodgkin lymphoma composed of small B-lymphocytes involving the red pulp of the spleen, bone marrow, and peripheral blood.  Patients often have massive splenomegaly.  The peripheral blood examination reveals villous lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Splenic Diffuse Red Pulp Small B-Cell Lymphoma","conceptCode":"C80309","definition":"An uncommon, indolent B-cell non-Hodgkin lymphoma composed of small B-lymphocytes involving the red pulp of the spleen, bone marrow, and peripheral blood.  Patients often have massive splenomegaly.  The peripheral blood examination reveals villous lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE35A9C-09D9-3EA2-E053-F662850A4384","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C279-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Splenic marginal zone lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2579748","version":"1","preferredName":"splenic marginal zone B-cell lymphoma","longName":"2579748","preferredDefinition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  The patients present with splenomegaly and the clinical course is indolent.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Splenic Marginal Zone Lymphoma","conceptCode":"C4663","definition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  When lymphoma cells are present in the peripheral blood, they are usually, but not always, characterized by the presence of short polar villi. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0491-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-15","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-15","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C27A-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Duodenal-type follicular lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"6002246","version":"1","preferredName":"Duodenal-Type Follicular Lymphoma","longName":"6002246","preferredDefinition":"A localized low-grade follicular lymphoma within the gastrointestinal tract, which is distinct from other gastrointestinal tract follicular lymphomas.  It has features that overlap with in situ follicular neoplasia as well as some features resembling an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. The prognosis is excellent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duodenal-Type Follicular Lymphoma","conceptCode":"C138185","definition":"A localized low-grade follicular lymphoma within the gastrointestinal tract, which is distinct from other gastrointestinal tract follicular lymphomas.  It has features that overlap with in situ follicular neoplasia as well as some features resembling an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. The prognosis is excellent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5912CE-9582-4D2E-E053-F662850A3D9C","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C27B-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Follicular, mixed, small cleaved and large cell (Grade II follicle center lymphoma)","valueDescription":null,"ValueMeaning":{"publicId":"3088717","version":"1","preferredName":"Grade 2 Follicular Lymphoma","longName":"3088717","preferredDefinition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 2 Follicular Lymphoma","conceptCode":"C8968","definition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E480BB-B6CD-7B51-E040-BB89AD433123","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C27C-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Follicular, predominantly large cell (Grade IIIA follicle center lymphoma)","valueDescription":null,"ValueMeaning":{"publicId":"3928530","version":"1","preferredName":"Grade 3a Follicular Lymphoma","longName":"3928530","preferredDefinition":"A grade 3 follicular lymphoma in which centrocytes are present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3a Follicular Lymphoma","conceptCode":"C7191","definition":"A grade 3 follicular lymphoma in which centrocytes are present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3D31-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C27D-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Follicular, predominantly large cell (Grade IIIB follicle center lymphoma)","valueDescription":null,"ValueMeaning":{"publicId":"3928528","version":"1","preferredName":"Grade 3b Follicular Lymphoma","longName":"3928528","preferredDefinition":"A grade 3 follicular lymphoma composed of solid sheets of centroblasts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3b Follicular Lymphoma","conceptCode":"C7192","definition":"A grade 3 follicular lymphoma composed of solid sheets of centroblasts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3D0B-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C27E-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Follicular, predominantly large cell (Grade IIIA vs IIIB not specified)","valueDescription":null,"ValueMeaning":{"publicId":"2593084","version":"1","preferredName":"Grade 3 Follicular Lymphoma","longName":"2593084","preferredDefinition":"A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3 Follicular Lymphoma","conceptCode":"C3460","definition":"A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A89-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C27F-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Follicular, predominantly small cleaved cell (Grade I follicle center lymphoma)","valueDescription":null,"ValueMeaning":{"publicId":"2593080","version":"1","preferredName":"Grade 1 Follicular Lymphoma","longName":"2593080","preferredDefinition":"A low-grade malignant lymphoma of predominantly follicular pattern. Follicles are of relatively uniform size and shape and the cells are usually somewhat larger than normal lymphocytes. Nuclei are irregular with prominent indentations and cytoplasm can rarely be identified. Cells exhibiting these characteristics are often called small cleaved cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1 Follicular Lymphoma","conceptCode":"C3465","definition":"A follicular lymphoma which contains up to 5 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A3B-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C280-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Pediatric-type follicular lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"5990036","version":"1","preferredName":"Pediatric Follicular Lymphoma","longName":"5990036","preferredDefinition":"A variant of follicular lymphoma often involving cervical or other peripheral lymph nodes and the Waldeyer ring. It is frequently localized, and lacks BCL-2 protein expression and 14;18 translocation.  It is seen in the pediatric population. The prognosis is usually favorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pediatric-Type Follicular Lymphoma","conceptCode":"C80297","definition":"A nodal follicular lymphoma with favorable prognosis. It lacks BCL-2 rearrangement and 14;18 translocation. Nearly all cases are localized. It is usually seen in the pediatric population but similar lymphomas may occur in adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE28B1A-8367-22A2-E053-F662850A8268","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C281-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Follicular (grade unknown)","valueDescription":null,"ValueMeaning":{"publicId":"3088584","version":"1","preferredName":"Follicular Lymphoma","longName":"3088584","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D19B-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C282-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary cutaneous follicle center lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"5989987","version":"1","preferredName":"Primary Cutaneous Follicle Center Lymphoma","longName":"5989987","preferredDefinition":"A primary lymphoma of the skin composed of various numbers of small and large irregular neoplastic follicle center cells.  Its morphologic pattern can be nodular, diffuse, or nodular and diffuse.  It presents with solitary or grouped plaques and tumors, and it usually involves the scalp, forehead, or trunk.  It rarely involves the legs.  This type of cutaneous lymphoma tends to remain localized to the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous Follicle Center Lymphoma","conceptCode":"C7217","definition":"A primary lymphoma of the skin composed of various numbers of small and large irregular neoplastic follicle center cells.  Its morphologic pattern can be nodular, diffuse, or nodular and diffuse.  It presents with solitary or grouped plaques and tumors, and it usually involves the scalp, forehead, or trunk.  It rarely involves the legs.  This type of cutaneous lymphoma tends to remain localized to the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE35A9C-098D-3EA2-E053-F662850A4384","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C283-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Mantle cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2838603","version":"1","preferredName":"Mantle Cell Lymphoma","longName":"2838603","preferredDefinition":"An aggressive, usually diffuse non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes).  Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement.  The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma.  The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mantle Cell Lymphoma","conceptCode":"C4337","definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE62-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C284-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Leukemic non-nodal mantle cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"14679095","version":"1","preferredName":"Leukemic Nonnodal Mantle Cell Lymphoma","longName":"14679095v1.00","preferredDefinition":"Mantle cell lymphoma involving the peripheral blood, bone marrow, and often spleen. It usually has an indolent clinical course.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemic Nonnodal Mantle Cell Lymphoma","conceptCode":"C138192","definition":"Mantle cell lymphoma involving the peripheral blood, bone marrow, and often spleen. It usually has an indolent clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0DB-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C285-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Transformations of indolent B-cell lymphomas","valueDescription":null,"ValueMeaning":{"publicId":"14679096","version":"1","preferredName":"Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","longName":"14679096v1.00","preferredDefinition":"Histologic transformation of an indolent B-cell non-Hodgkin lymphoma to an aggressive diffuse large B-cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","conceptCode":"C179717","definition":"Histologic transformation of an indolent B-cell non-Hodgkin lymphoma to an aggressive diffuse large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0DC-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C286-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Classical Hodgkin lymphoma PTLD","valueDescription":null,"ValueMeaning":{"publicId":"5990001","version":"1","preferredName":"Classical Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder","longName":"5990001","preferredDefinition":"An Epstein-Barr positive lymphoproliferation fulfilling the criteria for classical Hodgkin lymphoma and arising as a result of post-transplant immunosuppression therapy.  It is most often seen in renal transplant patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classic Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder","conceptCode":"C7243","definition":"A lymphoproliferative disorder that fulfills the criteria for classic Hodgkin lymphoma and arises as a result of post-transplant immunosuppression therapy. It is most often seen in renal transplant patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE2EBA8-4B9B-77B0-E053-F662850A6C58","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C287-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"EBV-positive mucocutaneous ulcer","valueDescription":null,"ValueMeaning":{"publicId":"5989999","version":"1","preferredName":"Epstein-Barr Virus-Positive Mucocutaneous Ulcer","longName":"5989999","preferredDefinition":"A rare Epstein-Barr virus-positive B-cell lymphoproliferative disorder which presents as an ulcerative mucocutaneous lesion. It is associated with immune suppression, including age-related and drug-induced immunosuppression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EBV-Positive Mucocutaneous Ulcer","conceptCode":"C131906","definition":"A rare Epstein-Barr virus-positive B-cell lymphoproliferative disorder that affects mucosal sites (including oral mucosa, palate, tonsils, and gastrointestinal tract) and skin. It presents with well-circumscribed, often painful ulcers. It is associated with immune suppression, including age-related and drug-induced immunosuppression. In the majority of cases the lesions regress either spontaneously or following withdrawal of the immunosuppression therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE36C42-4E95-4196-E053-F662850A806E","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C288-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Hyperplasia arising in immune deficiencies (e.g. PTLD)","valueDescription":null,"ValueMeaning":{"publicId":"14679097","version":"1","preferredName":"Immunodeficiency-Related Lymphoproliferative Disorder","longName":"14679097v1.00","preferredDefinition":"A lymphoproliferative disorder that occurs in a patient with immunodeficiency.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunodeficiency-Related Lymphoproliferative Disorder","conceptCode":"C150672","definition":"A lymphoproliferative disorder that occurs in a patient with immunodeficiency.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0DD-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C289-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Infectious mononucleosis PTLD","valueDescription":null,"ValueMeaning":{"publicId":"6002244","version":"1","preferredName":"Infectious Mononucleosis-Like Post-Transplant Lymphoproliferative Disorder","longName":"6002244","preferredDefinition":"An early post-transplant lymphoproliferative lesion characterized by immunoblastic proliferation and paracortical expansion as seen in infectious mononucleosis.  There is architectural preservation of the involved tissues.  Oligoclonal or monoclonal cellular populations have been detected in a small number of cases.  In some cases, a polymorphic or monomorphic post-transplant lymphoproliferative disorder may follow this early lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infectious Mononucleosis Post-Transplant Lymphoproliferative Disorder","conceptCode":"C7236","definition":"An early post-transplant lymphoproliferative lesion characterized by immunoblastic proliferation and paracortical expansion as seen in infectious mononucleosis.  There is architectural preservation of the involved tissues.  Oligoclonal or monoclonal cellular populations have been detected in a small number of cases.  In some cases, a polymorphic or monomorphic post-transplant lymphoproliferative disorder may follow this early lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5912CE-955C-4D2E-E053-F662850A3D9C","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C28A-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Monomorphic PTLD (B- and T-/NK-cell types)","valueDescription":null,"ValueMeaning":{"publicId":"4722713","version":"1","preferredName":"Monomorphic Post-Transplant Lymphoproliferative Disorder","longName":"4722713","preferredDefinition":"A clonal lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed lymphocytes or plasma cells.  It includes two variants: monomorphic B-cell and monomorphic T/NK cell post-transplant lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monomorphic Post-Transplant Lymphoproliferative Disorder","conceptCode":"C7233","definition":"A clonal lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed lymphocytes or plasma cells.  It includes two variants: monomorphic B-cell and monomorphic T/NK cell post-transplant lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C304-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C28B-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation","valueDescription":null,"ValueMeaning":{"publicId":"3249790","version":"1","preferredName":"Polymorphic Post-Transplant Lymphoproliferative Disorder","longName":"3249790","preferredDefinition":"A clonal B-cell lymphoproliferative disorder, characterized by destructive infiltration of lymph nodes and extranodal sites by a polymorphic B-cell infiltrate composed of small and medium sized lymphocytes, immunoblasts, and plasma cells, arising as a result of post-transplant immunosuppression therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymorphic Post-Transplant Lymphoproliferative Disorder","conceptCode":"C7183","definition":"A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a polymorphic B-cell infiltrate composed of small and medium sized lymphocytes, immunoblasts, and plasma cells. In some cases, reduction of the immunosuppression therapy may lead to regression of the lesions. In other cases the lesions may progress to lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6DC37F6-CF95-75B6-E040-BB89AD430517","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C28C-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Adult T-cell lymphoma / leukemia","valueDescription":null,"ValueMeaning":{"publicId":"4264852","version":"1","preferredName":"Adult T-Cell Leukemia/Lymphoma","longName":"4264852","preferredDefinition":"A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult T-Cell Leukemia/Lymphoma","conceptCode":"C3184","definition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-025B-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C28D-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Aggressive NK-cell leukemia","valueDescription":null,"ValueMeaning":{"publicId":"4419384","version":"1","preferredName":"Natural Killer cell leukemia","longName":"4419384","preferredDefinition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aggressive NK-Cell Leukemia","conceptCode":"C8647","definition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E368-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C28E-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"NK-large granular lymphocytic leukemia","valueDescription":null,"ValueMeaning":{"publicId":"5990034","version":"1","preferredName":"Chronic Lymphoproliferative Disorder of NK-Cells","longName":"5990034","preferredDefinition":"An Epstein-Barr negative disorder with a chronic clinical course affecting predominantly adults and characterised by the proliferation of large granular lymphocytes with natural killer cell immunophenotype.  The T-cell receptor genes are not rearranged and it is not clear whether this disorder is reactive or neoplastic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphoproliferative Disorder of NK-Cells","conceptCode":"C39591","definition":"An Epstein-Barr virus negative disorder with a chronic clinical course affecting predominantly adults and characterized by the proliferation of large granular lymphocytes with natural killer cell immunophenotype.  The T-cell receptor genes are not rearranged.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE4BAFE-F5B8-3D59-E053-F662850A1CD5","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C28F-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Sezary syndrome","valueDescription":null,"ValueMeaning":{"publicId":"3088586","version":"1","preferredName":"Sezary Syndrome","longName":"3088586","preferredDefinition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sezary Syndrome","conceptCode":"C3366","definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D1FF-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"ONEDATA","dateModified":"2010-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C290-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"T-large granular lymphocytic leukemia","valueDescription":null,"ValueMeaning":{"publicId":"2590775","version":"1","preferredName":"T-Cell Large Granular Lymphocyte Leukemia","longName":"2590775","preferredDefinition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Large Granular Lymphocyte Leukemia","conceptCode":"C4664","definition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F6CF08-5979-36DF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C291-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Mycosis fungoides","valueDescription":null,"ValueMeaning":{"publicId":"4264966","version":"1","preferredName":"Mycosis Fungoides","longName":"4264966","preferredDefinition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides","conceptCode":"C3246","definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3BBF-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C292-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary cutaneous acral CD8-positive lymphoproliferative disorder","valueDescription":null,"ValueMeaning":{"publicId":"6002240","version":"1","preferredName":"Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma","longName":"6002240","preferredDefinition":"A cutaneous T-cell lymphoma presenting as an acral (peripheral) lesion. It was originally described as originating in the ear and is usually localized to a single site. It is composed of CD8-positive neoplastic T-lymphocytes. It has an indolent clinical course.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous Acral CD8-Positive T-Cell Lymphoproliferative Disorder","conceptCode":"C139023","definition":"A primary cutaneous T-cell lymphoproliferative disorder that presents as an acral (peripheral) lesion. It is composed of CD8-positive neoplastic T-lymphocytes. It is usually localized to a single site and has an indolent clinical course. Local or more extensive recurrences have been described in a minority of patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5912CE-9510-4D2E-E053-F662850A3D9C","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C293-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder","valueDescription":null,"ValueMeaning":{"publicId":"5990005","version":"1","preferredName":"Primary Cutaneous CD4-Positive Small/Medium-Sized  T-Cell Lymphoproliferative Disorder","longName":"5990005","preferredDefinition":"A primary cutaneous T-cell lymphoproliferative disorder.  It usually presents with a solitary plaque or tumor on the face, neck, or upper trunk.  Morphologically, it is composed of small to medium-sized CD4-positive, CD8-negative, and CD30-negative pleomorphic T-lymphocytes.  A small number of large pleomorphic T-lymphocytes may also be present.  The lymphocytic infiltrate is dermal.  Focal epidermotropism and subcutaneous involvement may be present.  The clinical behavior is almost always indolent and most patients present with localized disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder","conceptCode":"C45366","definition":"A primary cutaneous T-cell lymphoproliferative disorder.  It usually presents with a solitary plaque or tumor on the face, neck, or upper trunk.  Morphologically, it is composed of small to medium-sized CD4-positive, CD8-negative, and CD30-negative pleomorphic T-lymphocytes.  A small number of large pleomorphic T-lymphocytes may also be present.  The lymphocytic infiltrate is dermal.  Focal epidermotropism and subcutaneous involvement may be present.  The clinical behavior is almost always indolent and most patients present with localized disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE3B826-4F31-458B-E053-F662850A09A4","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C294-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"5990007","version":"1","preferredName":"Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma","longName":"5990007","preferredDefinition":"An aggressive, epidermotropic primary cutaneous T-cell lymphoma.  It is characterized by the presence of eruptive papules and nodules, or tumors, which may be localized or disseminated.  Morphologically, it is composed of small to medium-sized, or medium-sized to large, CD8-positive T-lymphocytes with pleomorphic or blastic nuclei.  Epidermotropism is often pronounced.  Angiocentricity and angioinvasion may be present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma","conceptCode":"C45339","definition":"An aggressive, epidermotropic primary cutaneous T-cell lymphoma.  It is characterized by the presence of eruptive papules and nodules, or tumors, which may be localized or disseminated.  Morphologically, it is composed of small to medium-sized, or medium-sized to large, CD8-positive T-lymphocytes with pleomorphic or blastic nuclei.  Epidermotropism is often pronounced.  Angiocentricity and angioinvasion may be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE3B826-4F57-458B-E053-F662850A09A4","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C295-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis","valueDescription":null,"ValueMeaning":{"publicId":"2838593","version":"1","preferredName":"Lymphomatoid Papulosis","longName":"2838593","preferredDefinition":"This is a chronic, recurrent skin disease characterized by spontaneously regressing papules composed of an atypical CD30-positive T-cell population.  The disease is defined as an atypical lymphoproliferative process and usually has a benign course.  However, a minority of cases are clonal and can progress to frank lymphoma.  Low dose methotrexate and psoralen/UVA (PUVA) are the best available therapies.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphomatoid Papulosis","conceptCode":"C3721","definition":"A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules.  The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis.  In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30.  The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma.  Treatment options include low dose methotrexate and psoralen/UVA (PUVA).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F7CE-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C296-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2838708","version":"1","preferredName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","longName":"2838708","preferredDefinition":"An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","conceptCode":"C6860","definition":"An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-971A-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C297-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary cutaneous gamma / delta T-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"5990009","version":"1","preferredName":"Primary Cutaneous Gamma-Delta T-Cell Lymphoma","longName":"5990009","preferredDefinition":"An aggressive cutaneous lymphoma of mature, activated gamma/delta T-lymphocytes.  It usually presents with disseminated plaques and nodules.  Involvement of mucosal sites is frequent.  However, involvement of lymph nodes, spleen, or bone marrow is uncommon.  Morphologically, there are three patterns of cutaneous involvement: epidermotropic, dermal, and subcutaneous.  Often, more than one pattern may co-exist in a single biopsy specimen, or may be present in different biopsy specimens from the same patient.  The lymphocytic infiltrate is composed of medium- to large-sized lymphocytes expressing CD56.  Most cases lack both CD4 and CD8, although CD8 may be present in some cases.  This group of lymphomas includes cases previously known as subcutaneous panniculitis-like T-cell lymphoma with a gamma/delta phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous Gamma-Delta T-Cell Lymphoma","conceptCode":"C45340","definition":"An aggressive cutaneous lymphoma of mature, activated gamma/delta T-lymphocytes.  It usually presents with disseminated plaques and nodules.  Involvement of mucosal sites is frequent.  However, involvement of lymph nodes, spleen, or bone marrow is uncommon.  Morphologically, there are three patterns of cutaneous involvement: epidermotropic, dermal, and subcutaneous.  Often, more than one pattern may co-exist in a single biopsy specimen, or may be present in different biopsy specimens from the same patient.  The lymphocytic infiltrate is composed of medium- to large-sized lymphocytes expressing CD56.  Most cases lack both CD4 and CD8, although CD8 may be present in some cases.  This group of lymphomas includes cases previously known as subcutaneous panniculitis-like T-cell lymphoma with a gamma/delta phenotype.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE3B826-4F7D-458B-E053-F662850A09A4","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C298-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Subcutaneous panniculitis-like T-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2838852","version":"1","preferredName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","longName":"2838852","preferredDefinition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","conceptCode":"C6918","definition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-3A15-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C299-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Primary cutaneous peripheral T-cell lymphoma, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"14679098","version":"1","preferredName":"Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified","longName":"14679098v1.00","preferredDefinition":"An exceedingly rare peripheral T-cell lymphoma that arises from the skin and does not meet the criteria that define the other well characterized primary cutaneous peripheral T-cell lymphomas, i.e., it is a diagnosis of exclusion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C201080","definition":"An exceedingly rare peripheral T-cell lymphoma that arises from the skin and does not meet the criteria that define the other well characterized primary cutaneous peripheral T-cell lymphomas, i.e., it is a diagnosis of exclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0DE-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C29A-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Enteropathy-associated T-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"3322761","version":"1","preferredName":"Enteropathy-Associated T-Cell Lymphoma","longName":"3322761","preferredDefinition":"An uncommon mature T-cell lymphoma of intraepithelial lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum. Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is seen with increased frequency in regions with a high prevalence of celiac disease. The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enteropathy-Associated T-Cell Lymphoma","conceptCode":"C4737","definition":"A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is characterized by the presence of pleomorphic medium-sized to large T-lymphocytes with vesicular nuclei, prominent nucleoli, and moderate to abundant pale cytoplasm. It is associated with celiac disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A7B3-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C29B-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Indolent T-cell lymphoma of the gastrointestinal tract","valueDescription":null,"ValueMeaning":{"publicId":"6002238","version":"1","preferredName":"Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","longName":"6002238","preferredDefinition":"A clonal lymphoproliferative disorder affecting many sites of the gastrointestinal tract. It can be derived from either CD8 or less often CD4 positive T cells. It has an indolent clinical course.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indolent Clonal T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","conceptCode":"C139021","definition":"A clonal T-cell lymphoproliferative disorder that can involve the mucosa in all sites of the gastrointestinal tract, but is most common in the small intestine and colon. The lymphoid cells infiltrate the lamina propria but usually do not show invasion of the epithelium. The clinical course is indolent, but most patients do not respond to conventional chemotherapy. A subset of cases progress to a higher-grade T-cell lymphoma with spread beyond the gastrointestinal tract. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5912CE-94EA-4D2E-E053-F662850A3D9C","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C29C-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract","valueDescription":null,"ValueMeaning":{"publicId":"14679099","version":"1","preferredName":"Indolent NK-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","longName":"14679099v1.00","preferredDefinition":"An indolent lymphoproliferative disorder that affects the gastrointestinal tract. The neoplastic lymphocytes have the typical phenotype of NK-cells, are of medium to large size, show mild pleomorphism, and are EBV infection negative. Features that characterize extranodal NK/T-cell lymphomas (e.g., angioinvasion and angiodestruction) are not present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indolent NK-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","conceptCode":"C200037","definition":"An indolent lymphoproliferative disorder that affects the gastrointestinal tract. The neoplastic lymphocytes have the typical phenotype of NK-cells, are of medium to large size, show mild pleomorphism, and are EBV infection negative. Features that characterize extranodal NK/T-cell lymphomas (e.g., angioinvasion and angiodestruction) are not present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0DF-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C29D-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Monomorphic epitheliotropic intestinal T-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"5990030","version":"1","preferredName":"Monomorphic CD56+ Intestinal T-Cell Lymphoma","longName":"5990030","preferredDefinition":"A primary small intestinal T-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes.  It is characterized by the presence of small to medium sized T lymphocytes that are cytotoxic and express CD56.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma","conceptCode":"C96058","definition":"A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine. A minority of cases arise from the large intestine or the stomach. It is characterized by the presence of a monomorphic cellular infiltrate of small to medium-sized T-lymphocytes that are cytotoxic and express CD56. It is not associated with celiac disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE48C78-28E6-21E5-E053-F662850A74A8","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C29E-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Intestinal T-cell lymphoma, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"14679100","version":"1","preferredName":"Intestinal T-Cell Lymphoma, Not Otherwise Specified","longName":"14679100v1.00","preferredDefinition":"A T-cell lymphoma arising in the intestines, or sometimes other sites in the gastrointestinal tract, that does not conform to either classic enteropathy-associated T-cell lymphoma or monomorphic epitheliotropic intestinal T-cell lymphoma. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intestinal T-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C150505","definition":"A T-cell lymphoma arising in the intestines, or sometimes other sites in the gastrointestinal tract, that does not conform to either classic enteropathy-associated T-cell lymphoma or monomorphic epitheliotropic intestinal T-cell lymphoma. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0E0-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C29F-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Hepatosplenic T-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2838581","version":"1","preferredName":"Hepatosplenic T-Cell Lymphoma","longName":"2838581","preferredDefinition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatosplenic T-Cell Lymphoma","conceptCode":"C8459","definition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-58F8-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2A0-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"ALK-positive anaplastic large cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"3928516","version":"1","preferredName":"Anaplastic Large Cell Lymphoma, ALK-Positive","longName":"3928516","preferredDefinition":"A T-cell peripheral lymphoma composed of usually large, pleomorphic, CD30 positive T-lymphocytes with abundant cytoplasm characterized by the presence of a translocation involving the ALK gene and expression of ALK fusion protein.  Most patients present with peripheral and/or abdominal lymphadenopathy, and often have advanced disease and extranodal involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Large Cell Lymphoma, ALK-Positive","conceptCode":"C37193","definition":"A T-cell peripheral lymphoma composed of usually large, pleomorphic, CD30 positive T-lymphocytes with abundant cytoplasm. It is characterized by the presence of a translocation involving the ALK gene and expression of ALK fusion protein. Most patients present with peripheral and/or abdominal lymphadenopathy, and often have advanced disease and extranodal involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3BCD-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2A1-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"ALK-negative anaplastic large-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"3928514","version":"1","preferredName":"Anaplastic Large Cell Lymphoma, ALK-Negative","longName":"3928514","preferredDefinition":"A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive.  It is characterized by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Large Cell Lymphoma, ALK-Negative","conceptCode":"C37194","definition":"A T-cell peripheral lymphoma morphologically indistinguishable from anaplastic large cell lymphoma, ALK-positive.  It is characterized by the absence of the translocation involving the ALK gene and lacks expression of ALK fusion protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96DEF43-3BA7-7609-E040-BB89AD4366AC","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2A2-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Breast implant-associated anaplastic large cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"6002234","version":"1","preferredName":"Breast Implant-Associated Anaplastic Large Cell Lymphoma","longName":"6002234","preferredDefinition":"A rare anaplastic large cell lymphoma that can develop following breast implants. It has been reported in patients with saline-and silicone-filled implants. It usually presents as an accumulation of seroma fluid between the implant and the surrounding fibrous capsule. The median interval from the time of the implant to the development of lymphoma is approximately 10 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Implant-Associated Anaplastic Large Cell Lymphoma","conceptCode":"C139012","definition":"A rare anaplastic large cell lymphoma that develops in individuals with breast implants. It usually presents as an accumulation of seroma fluid between the implant and the surrounding fibrous capsule. The median interval from the time of the implant to the development of lymphoma is approximately 10 years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5912CE-949E-4D2E-E053-F662850A3D9C","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2A3-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Nodal TFH cell lymphoma, angioimmunoblastic-type","valueDescription":null,"ValueMeaning":{"publicId":"3088583","version":"1","preferredName":"Angioimmunoblastic T-Cell Lymphoma","longName":"3088583","preferredDefinition":"A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes and extranodal sites.  The clinical course is typically aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","conceptCode":"C7528","definition":"An aggressive follicular helper T-cell lymphoma affecting lymph nodes and other sites. It is characterized by a polymorphous infiltrate and prominent proliferation of high endothelial venules and follicular dendritic cells. It is associated with EBV infection and affects mainly older adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D15A-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2A4-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Nodal TFH cell lymphoma, follicular-type","valueDescription":null,"ValueMeaning":{"publicId":"5990022","version":"1","preferredName":"Follicular Variant Peripheral T-Cell Lymphoma","longName":"5990022","preferredDefinition":"A variant of peripheral T-cell lymphoma, not otherwise specified.  It is characterized by the formation of nodular lymphocytic aggregates of atypical clear cells, either within the lymphoid follicles in a background of progressive transformation of germinal centers, or in the perifollicular areas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Helper T-Cell Lymphoma, Follicular-Type","conceptCode":"C80375","definition":"Follicular helper T-cell lymphoma with a predominantly follicular growth pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE4228F-5959-2DAA-E053-F662850A70BC","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2A5-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Nodal TFH cell lymphoma, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"6002236","version":"1","preferredName":"Nodal Peripheral T-Cell Lymphoma with TFH Phenotype","longName":"6002236","preferredDefinition":"A nodal peripheral T-cell non-Hodgkin lymphoma in which the neoplastic lymphocytes manifest a T Follicular Helper (TFH) Phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Helper T-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C139011","definition":"Follicular helper T-cell lymphoma that does not meet the criteria for any other specifically defined entity of follicular helper T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5912CE-94C4-4D2E-E053-F662850A3D9C","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2A6-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Peripheral T-cell lymphoma, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"4173735","version":"1","preferredName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","longName":"4173735","preferredDefinition":"Aggressive nodal or extranodal mature (peripheral) T-cell lymphomas that do not belong to the better defined entities of the remainder of mature T-cell lymphomas.  This category includes the following variants: lymphoepithelioid cell variant (Lennert's lymphoma), follicular variant, and T-zone variant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C4340","definition":"A group of peripheral T-cell lymphomas that do not meet the criteria for any other category of specifically defined entities of peripheral T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F33D84E5-7AD8-4906-E040-BB89AD434E8B","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2A7-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"EBV-positive nodal T- and NK-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"14679101","version":"1","preferredName":"Primary EBV-Positive Nodal T-Cell or NK-Cell Lymphoma","longName":"14679101v1.00","preferredDefinition":"An EBV-positive peripheral T-cell lymphoma that arises from the lymph nodes. It is characterized by a monomorphic pattern of infiltration and abscence of the angiodestruction and necrosis seen in extranodal NK/T-cell lymphomas. These lymphomas are more common in elderly patient, or in the setting of immune deficiency. For the time being, they are considered a variant of peripheral T-cell lymphoma, not otherwise specified. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary EBV-Positive Nodal T-Cell or NK-Cell Lymphoma","conceptCode":"C139288","definition":"An EBV-positive peripheral T-cell lymphoma that arises from the lymph nodes. It is characterized by a monomorphic pattern of infiltration and abscence of the angiodestruction and necrosis seen in extranodal NK/T-cell lymphomas. These lymphomas are more common in elderly patient, or in the setting of immune deficiency. For the time being, they are considered a variant of peripheral T-cell lymphoma, not otherwise specified. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F2466FC-A0E1-1BBD-E063-731AD00AB357","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2A8-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Extranodal NK / T-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2593089","version":"1","preferredName":"Nasal Type Extranodal NK/T-Cell Lymphoma","longName":"2593089","preferredDefinition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma.  It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells.  The nasal cavity is the commonest site of involvement.  Patients often present with midfacial destructive lesions (lethal midline granuloma).  The disease may disseminate rapidly to various anatomic sites including gastrointestinal tract, skin, testis, and cervical lymph nodes.  It is also known as angiocentric T-cell lymphoma.  The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma.  However, the latter term may also apply to lymphomatoid granulomatosis which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasal Type Extranodal NK/T-Cell Lymphoma","conceptCode":"C4684","definition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma. It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells. The nasal cavity is the most common site of involvement. Patients often present with midfacial destructive lesions (lethal midline granuloma). The disease may disseminate rapidly to various anatomic sites including the gastrointestinal tract, skin, testis, and cervical lymph nodes. It is also known as angiocentric T-cell lymphoma. The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma. However, the latter term may also apply to lymphomatoid granulomatosis, which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286BA529-8F3E-7325-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2A9-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Systemic EBV+ T-cell lymphoma of childhood","valueDescription":null,"ValueMeaning":{"publicId":"5990011","version":"1","preferredName":"Systemic EBV-Positive T-Cell Lymphoproliferative Disease of Childhood","longName":"5990011","preferredDefinition":"An aggressive and life-threatening, EBV-positive T-cell lymphoproliferative disorder affecting children.  It is more prevalent in Taiwan and Japan.  Clinically, it presents with acute onset of fever and generalized malaise, followed by hepatosplenomegaly and liver failure.  Morphologically it is characterized by the presence of infiltrating T-lymphocytes which are usually small and erythrophagocytosis.  Most patients have a fulminant clinical course.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic EBV-Positive T-Cell Lymphoma of Childhood","conceptCode":"C80374","definition":"An aggressive and life-threatening, EBV-positive T-cell lymphoma affecting children.  It is more prevalent in Taiwan and Japan.  Clinically, it presents with acute onset of fever and generalized malaise, followed by hepatosplenomegaly and liver failure.  Morphologically it is characterized by the presence of infiltrating T-lymphocytes which are usually small and erythrophagocytosis.  Most patients have a fulminant clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AE3CC3C-9BF0-3E53-E053-F662850A6BF9","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2AA-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Other B-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2672876","version":"1","preferredName":"Other B-Cell Non-Hodgkin Lymphoma","longName":"2672876","preferredDefinition":"Not otherwise specified.: The most common type of non-Hodgkin lymphoma.  It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"B-Cell Non-Hodgkin Lymphoma","conceptCode":"C3457","definition":"The most common type of non-Hodgkin lymphoma.  It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37D2B09F-55E7-195D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2AB-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Other T-cell / NK-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"3113374","version":"1","preferredName":"Other T-Cell Non-Hodgkin Lymphoma","longName":"3113374","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A non-Hodgkin lymphoma of T-cell lineage.  It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"T-Cell Non-Hodgkin Lymphoma","conceptCode":"C3466","definition":"A non-Hodgkin lymphoma of T-cell lineage. It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89A00FFB-4682-5A58-E040-BB89AD430BEA","latestVersionIndicator":"Yes","beginDate":"2010-06-22","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F24ED9C-C2AC-34C2-E063-731AD00A159A","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL6 rearrangements","valueDescription":null,"ValueMeaning":{"publicId":"14679104","version":"1","preferredName":"High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements","longName":"14679104v1.00","preferredDefinition":"High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC and BCL6 genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements","conceptCode":"C199618","definition":"High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC and BCL6 genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F250EC2-99C0-3AA5-E063-731AD00A0E35","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F250EC2-99C2-3AA5-E063-731AD00A0E35","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Fluid overload-associated large B-cell lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"14679105","version":"1","preferredName":"HHV-8 and EBV-Negative Primary Effusion-Based Lymphoma","longName":"14679105v1.00","preferredDefinition":"An HHV-8 and EBV-negative primary effusion-based lymphoma that affects elderly, HIV-negative patients with history of medical conditions that result in fluid overload. The majority of cases have been reported in Japan. Most tumors exhibit centroblastic or immunoblastic morphology. The prognosis is good.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HHV-8 and EBV-Negative Primary Effusion-Based Lymphoma","conceptCode":"C199576","definition":"An HHV-8 and EBV-negative primary effusion-based lymphoma that affects elderly, HIV-negative patients with history of medical conditions that result in fluid overload. The majority of cases have been reported in Japan. Most tumors exhibit centroblastic or immunoblastic morphology. The prognosis is good.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F250EC2-99C1-3AA5-E063-731AD00A0E35","latestVersionIndicator":"Yes","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F250EC2-99C3-3AA5-E063-731AD00A0E35","beginDate":"2024-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3411941","version":"1","preferredName":"Lymphoma Histology Classification Type","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.:The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.:A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:Something distinguishable as an identifiable class based on common qualities.","longName":"C3208:C16681:C25161:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Histology","conceptCode":"C16681","definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BABD4153-7770-69FD-E040-BB89AD43286F","latestVersionIndicator":"Yes","beginDate":"2012-03-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-03-08","modifiedBy":"ONEDATA","dateModified":"2012-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0F2427D0-A8E7-0DE0-E063-731AD00AF3C0","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":"Versioned due to change out in concept. AK 4/30/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964890","version":"1","longName":"2018r1: Lymphoma Pre-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]},{"publicId":"6705584","version":"1","longName":"CCG PTCL (Center for Cancer Genomics - Peripheral T Cell Lymphoma)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6705585","version":"1","longName":"PTCL","context":"NCIP"}]}],"AlternateNames":[{"name":"LYMpre_assess_transform_lym_histol_transform_type","type":"NMDP_FN","context":"NHLBI"},{"name":"LYMpre_ASDG_lymph_histol_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"LYMpre_assess_diag_histol_type","type":"NMDP_FN","context":"NHLBI"},{"name":"LYMpre_astrn_lymphoma_hist_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedClinicalResult:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"TDIS_LYM_tran_lymph_histol_typ","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_LYM_tx_lymph_histol_type","type":"NMDP_FN","context":"NHLBI"},{"name":"LYMpre_assess_diag_lymph_histology_type","type":"NMDP_FN","context":"NHLBI"},{"name":"DZ_DIS_LYMP_HX","type":"OID, Theradex","context":"Theradex"},{"name":"DLBL0102","type":"OID, Theradex","context":"Theradex"}],"ReferenceDocuments":[{"name":"Specify the original lymphoma histology","type":"Alternate Question Text","description":"Specify the original lymphoma histology","url":null,"context":"NHLBI"},{"name":"Histology:","type":"Alternate Question Text","description":"Histology:","url":null,"context":"NHLBI"},{"name":"PQT","type":"Preferred Question Text","description":"What is the lymphoma histology classification?","url":null,"context":"NHLBI"},{"name":"What was the lymphoma histology?","type":"Alternate Question Text","description":"What was the lymphoma histology?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2950698","type":"BRIDG Mapping Path","description":"PerformedClinicalResult.value WHERE PerformedClinicalResult > PerformedObservation > DefinedObservation.nameCode = \"Measure Lymphoma Histology Type\"","url":null,"context":"NHLBI"},{"name":"What was the lymphoma histology?","type":"Application Standard Question Text","description":"What was the lymphoma histology?","url":null,"context":"NHLBI"},{"name":"Specify the lymphoma histology","type":"Alternate Question Text","description":"Specify the lymphoma histology","url":null,"context":"NHLBI"},{"name":"Specify the lymphoma histology at diagnosis","type":"Alternate Question Text","description":"Specify the lymphoma histology at diagnosis","url":null,"context":"NHLBI"},{"name":"What was the lymphoma histology at transformation?","type":"Alternate Question Text","description":"What was the lymphoma histology at transformation?","url":null,"context":"NHLBI"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"What was the lymphoma histology at diagnosis?","url":null,"context":"Theradex"},{"name":"Histological subtype of the lymphoma","type":"Alternate Question Text","description":"Histological subtype of the lymphoma","url":null,"context":"NCIP"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Histology/Cytopathology","url":null,"context":"Theradex"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0F254954-FCC5-47EC-E063-731AD00A34BB","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-17","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":".ALT name added for 2018r6. 12/21/2020 KMM","administrativeNotes":"2024.1.17 Created per ticket request CADSR0003263. ak","unresolvedIssues":null,"deletedIndicator":"No"}}